Navigation Links
Regeneron Reports First Quarter 2013 Financial and Operating Results
Date:5/3/2013

commercialization of EYLEA and higher non-cash share-based compensation expense.  In the first quarter of 2013, SG&A related non-cash share-based compensation expense was $26 million, compared to $13 million in the first quarter of 2012.Cost of Goods Sold (COGS): GAAP COGS was $29 million in the first quarter of 2013, compared to $12 million in the first quarter of 2012.  The increase was due to higher EYLEA sales in 2013.

Interest Expense: GAAP interest expense was $12 million in the first quarter of 2013, compared to $11 million in the first quarter of 2012.  In connection with the Company's convertible senior notes, which were issued in October 2011, the Company incurred interest expense of $8 million in the first quarter of 2013, which included $6 million of non-cash interest expense.  In the first quarter of 2012, the Company incurred interest expense of $7 million related to the Company's convertible senior notes, which included $5 million of non-cash interest expense.

Income Tax Expense: GAAP income tax expense was $43 million in the first quarter of 2013.
The effective tax rate of 30.3% for the quarter includes the impact of The American Taxpayer Relief Act, which was enacted in January 2013, and retroactively extended various expiring tax provisions, including the credit for increased research activities.  As a result, during the first quarter of 2013, the Company recognized the benefit of its full year 2012 federal research tax credit.

In the first quarter of 2012, the Company continued to recognize a full valuation allowance against its net operating loss carry-forward and other deferred tax assets since the Company had an extended history of losses.  In the fourth quarter of 2012, the Company recorded an income tax benefit attributable to the release of substantially all of the remaining valuation allowance against the Company's deferred tax assets.  The decision to reverse the valuation allo
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Regeneron Pharmaceuticals’ Industrial Operations & Product Supply Site Receives International Recognition for Operational Excellence
2. Sanofi and Regeneron Launch Comprehensive Phase 3 Clinical Program With LDL Cholesterol-Lowering PCSK9 Antibody
3. Sanofi and Regeneron Announce Publication of Positive Phase 2 Results for Lipid-Lowering PCSK9 Antibody in The Lancet
4. Regeneron Announces March 2012 Investor Conference Presentations
5. Regeneron Announces Presentation at the Leerink Swann 2012 Global Healthcare Conference
6. Cadence Pharmaceuticals Reports First Quarter 2013 Financial Results
7. Agendia Reports More Than 20,000 MammaPrint Breast Cancer Recurrence Results
8. PAREXEL International Reports Third Quarter Fiscal Year 2013 Results
9. Cytos Biotechnology Ltd Reports First Quarter 2013 Financial Results and Recent Development
10. InterMune Reports First Quarter 2013 Financial Results and Business Highlights
11. Cord Blood Banking Industry: 2013 Growth Opportunities Analysis in New Market Research Report at ReportsnReports.com
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 ­ RedBrick Health , ... change technology, today announces that EmblemHealth , the ... wellness company, is now providing the RedBrick Compass health ... program, to all of its members. EmblemHealth is among ...
(Date:1/15/2014)... 2014 Two champions of science, technology, ... of an annual competition for middle and high school ... innovative STEM study. The competition presents students with real-world ... Engineering Aptitude, Mathematics, and Sciences is a program ...
(Date:1/15/2014)... (PRWEB) January 15, 2014 Freeslate, ... solutions, today announced that Lupin Limited, one of India’s ... CM Protégé PharmD System for high throughput ... India, is focused on a wide range of quality, ...
(Date:1/14/2014)... 2014 Carahsoft and CDS Federal Services ... 2014 at 2pm EST (11am PST), “Natural Language Processing: ... on how technology can turn raw, heterogeneous data into ... agencies. The online webinar will last approximately one hour. ...
Breaking Biology Technology:EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 2EmblemHealth Selects RedBrick Health to Power its Next-Generation Health Engagement and Behavior Change System 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 2Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 3Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 4Technology Student Association Partners with Leaders in STEM Education Advocacy for Annual Competition 5Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 2Lupin Selects Freeslate’s CM Protégé PharmD System to Accelerate Polymorph Screening for Drug Development 3Webcast - Natural Language Processing: Converting Raw Data into Actionable Knowledge – Hosted by Carahsoft and CDS Federal Services 2
... do Dr. Peper, Dr. Sigmund Freud and Arnold Schwarzenegger ... be surprised to learn that Europeans love Dr. Peper. ... Erik Peper, President of the Biofeedback Foundation of Europe ... Dr. Erik Peper opens the 13th Annual Conference of ...
... Presents on Therapy Development StrategyCAMBRIDGE, Mass., Feb. 17 ... has announced the 2009 launch of its popular ... seminar is designed to inform and update patients, ... to discover and develop effective treatments for amyotrophic ...
... Inc. (OTC Bulletin Board: GNPH) ("Genesis" or the,"Company"), a ... Republic of China, today announced its financial results for ... 31, 2008. , , Second Quarter ... Revenue was $32.9 million, up 24.1% from the corresponding ...
Cached Biology Technology:Dr. Peper, Dr. Freud and Arnold Schwarzenegger 2Seminar Will Bring ALS Researchers to Patient Groups 2Seminar Will Bring ALS Researchers to Patient Groups 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 2Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 3Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 4Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 5Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 6Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 7Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 8Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 9Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 10Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 11Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 12Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 13Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 14Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 15Genesis Pharmaceuticals Reports Results for the Second Quarter of its Fiscal Year 2009 16
(Date:4/17/2014)... April 17, 2014The development of stem cell therapies to ... to characterize stem cell populations based on cell surface ... a new marker that is highly expressed in a ... blood, which they describe in an article in ... Ann Liebert, Inc., publishers. The article is available free ...
(Date:4/17/2014)... Marc Andr Gauthier and Professor Luca Razzari of ... been awarded large grants from the John R. ... Innovation (CFI) for the acquisition of state-of-the-art biotech ... added matching grants from the Ministre de l,Enseignement ... de la Technologie (MESRST). These new laboratories will ...
(Date:4/17/2014)... news release is available in German . ... us to recognise objects; they also provide us with a ... run, turn around, fall or sit still in a car ... motion trace on our retinas. Seemingly without effort, our brain ... maintain a stable position and a steady gaze during our ...
Breaking Biology News(10 mins):New state-of-the-art biotech and nanotech equipment for INRS 2How vision makes sure that little fish do not get carried away 2How vision makes sure that little fish do not get carried away 3How vision makes sure that little fish do not get carried away 4
... NARRAGANSETT, RI -- June 7, 2011 -- Sunshine Menezes, executive ... and 2010 Grantham Prize winner Alanna Mitchell announced the 2011 ... the Environment. James Astill of The Economist will receive US$75,000 ... a commanding 8-part special report on the state of global ...
... in billionths of a meter, self-assembling nano-sized devices designed ... are revolutionizing medicine by improving drug solubility and bio-distribution, ... and enabling membrane barriers to be crossed as well ... Self-assembling nano devices are now enlisted in the ...
... turns out, humans aren,t the only organisms that turn to ... four different bacteria that actually can live on caffeine. ... was found in a flowerbed outside a UI research laboratory. ... understanding of how the process works -- could in the ...
Cached Biology News:$75,000 Grantham Prize winner announced 2$75,000 Grantham Prize winner announced 3Super-mini vehicles carry therapeutics and imaging agents into body with mega results 2University of Iowa researchers identify caffeine-consuming bacterium 2
DryStrip aligners, 4. Category: Electrophoresis Systems & Standards & Reagents, IEF & SDS-PAGE & 2-D Electrophoresis, Multiphor II Kits & Components and Accessories....
...
...
Antibodies were affinity purified using epitopes specific to QKI immobilized on solid support....
Biology Products: